NCT03811613

Photobiomodulation and Parkinson

Photobiomodulation in Parkinson´s Disease: A Randomized Controlled Trial.

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: University of Oviedo · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

This study aimed to assess the effects of transcranial photobiomodulation in patients with Parkinson's disease (PD).

Detailed description

Thirty-five patients with idiopathic PD were randomly assigned to a photobiomodulation (n=17, \[mean±SD\] 72±7 years) or sham group (n=18, 70±8 years) during 9 weeks (2 sessions/week). The primary endpoint was the motor portion of the Movement Disorders Society-United PD Rating Scale. Secondary endpoints were the Scales for Outcomes in PD, static posturography, walking ability (ten-meter walk test \[TMWT\]) and functional mobility (timed up and go \[TUG\] test).

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
OTHER	Transcranial photobiomodulation	Photobiomodulation was administered using red light-emitting diodes (LEDs) with a 670-nm wavelength (which has proven to penetrate the skull)

Timeline

• Start date: 2018-01-29
• Primary completion: 2018-03-30
• Completion: 2018-03-30
• First posted: 2019-01-22
• Last updated: 2025-05-21

Locations

2 sites across 1 country: Spain